InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,725.60
(
0.48%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.13
(
0.21%
)
Bitcoin
63,068.14
(
0.03%
)
Post# of 1990
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

JJCook

Send PM Follow Ignore
Followers 5
Posts 179
Boards Moderated 0
Alias Born 11/19/2017

JJCook

Re: TheShadow post# 1131

Tuesday, 11/28/2017 11:44:11 AM

Tuesday, November 28, 2017 11:44:11 AM

Post# of 1990
The Phase III trial is continuing and the company expects results to be good.
"Following the IDMC interim analysis, the Company met with the FDA to discuss the ADAPT trial and the future direction of the Rocapuldencel-T program in April 2017. The FDA agreed with the Company’s decision to continue the ADAPT trial, and further agreed to review a protocol amendment to extend the trial beyond the originally targeted 290 events and a revised statistical analysis plan that the Company plans to submit".
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up